Hypertension is an established risk factor for stroke and other cerebrovascular disorders. Both stroke and small lacunar infarcts or white matter lesions can cause cognitive impairment and dementia, and there is evidence that vascular risk factors play a major role in the development of both Alzheimer's disease and vascular dementia. Several large epidemiological studies have shown that raised blood pressure in midlife is a strong risk factor for dementia later in life; however, blood pressure often decreases following the development of dementia. The cognitive function hypothesis proposes that elevated blood pressure increases the risk of decline of cognitive function, and that this can be reversed by active lowering of blood pressure. Evidence in support of this hypothesis comes from the Syst-Eur
Introduction
The proportion of elderly people in the population is growing in most developed countries, due to increasing longevity and falling birth rates. An ageing population imposes substantial demands on health care resources, and represents one of the most important problems facing modern medicine. Given the substantial burden of mortality and morbidity associated with hypertension and related disease, effective control of raised blood pressure and prevention of target organ damage are important therapeutic goals in elderly patients. In this respect, evidence that antihypertensive treatment may prevent or reverse cognitive impairment and the development of dementia has focused attention on this potential benefit of antihypertensive therapy.
Hypertension in the elderly
The relationship between blood pressure and ageing is well established. Data from the Framingham Study, for example, show that systolic blood pressure increases progressively with age from the fourth to the seventh decade of life; diastolic blood pressure reaches a peak earlier, and declines after the age of about 60-65 years. 1 More recent data have confirmed a high prevalence of hypertension in the elderly. Data from the NHANES III Study in the United States, for example, show that hypertension (defined as a blood pressure of 140/90 mm Hg or above) is present in approximately 60-70% of elderly persons, depending on the ethnic group studied. 2 As a result of the decline in diastolic blood pressure seen after the age of 60-65 years, isolated systolic hypertension is a common finding in elderly patients, and this has been shown to influence cardiovascular risk more strongly than diastolic hypertension. 
Hypertension and dementia
Hypertension is a major risk factor for stroke in elderly patients, and this can have a number of neurological consequences, including cognitive impairment and the eventual development of dementia (Table 1 ). In addition, hypertension may be associated with small lacunar infarcts or white matter lesions that cause more limited neurological Dementia is defined as memory impairment combined with one or more deficits in higher mental functions, such as impaired abstract thinking or judgement, higher cortical disturbances such as aphasia or agnosia, or personality changes. 4 This combination of memory loss and cognitive impairment results in substantial disruption to the patient's daily life and activities. Primary dementias are classified into three main groups:
• primary degenerative dementias, principally
Alzheimer's disease and frontal lobe dementia; • vascular dementia;
• mixed Alzheimer's and vascular dementia.
In addition, secondary dementias can occur through a variety of causes, including normal pressure hydrocephalus, metabolic disorders, deficiency diseases, brain tumours or trauma.
The prevalence of dementia approximately doubles with every 5.1 years of age. 5 Moderate-tosevere dementia is present in 0.7% of people aged 60-64 years, and the prevalence increases to 5.6% at the age of 75-79 years and 38.6% at the age of 90-95 years. 5 Recent studies have shown that vascular risk factors play a major role in the development of Alzheimer's disease (Table 2 ). In particular, hypertension, atherosclerosis, coronary heart disease and diabetes are important risk factors. [6] [7] [8] In the population-based Rotterdam Study, for example, the risk of Alzheimer's disease was increased three-fold in subjects with atherosclerosis, compared with those without atherosclerosis, and the risk was increased still further in subjects with the apolipoprotein E ⑀4 genotype. 7 Similarly, in a study in women aged 76-100 years in the US (the Nun Study), atherosclerosis in the circle of Willis, associated with lesions in cerebral microvessels, was a strong predictor of the presence and severity of Alzheimer's disease. 8 Longitudinal studies have shown that elevated blood pressure in midlife is associated with cognitive impairment later in life. 9, 10 Data from the Framingham Study, for example, have shown an inverse correlation between untreated blood pressure and cognitive function. 9 Similarly, in the Honolulu-Asia Aging Study, the risk of intermediate or poor cognitive function increased by 7% and 9%, respectively, for every 10 mm Hg in midlife systolic blood pressure; the authors of this study concluded, therefore, that early control of systolic blood pressure might reduce the risk of cognitive impairment in old age. 10 A further study investigated the relationship between blood pressure and the development of dementia in residents of Gothenberg, Sweden. 11 In this study, blood pressure and cognitive function were assessed in 382 initially non-demented participants at the ages of 70, 75, 79 and 85 years. Patients who developed dementia between the ages of 79 and 85 years had higher systolic and diastolic blood pressures at the ages of 70 and 75 years than those who did not develop dementia (Figure 1 ). A group of 15 patients with suspected dementia underwent computed tomography (CT) at the age of 85 years, and 10 of these were found to have white matter lesions. These patients had significantly higher systolic and diastolic blood pressures at the age of 70 years than patients without such lesions. Furthermore, there was a significant decrease in both systolic and diastolic blood pressure between the ages of 70 and 85 years in these patients; the decrease in diastolic blood pressure was significantly greater than in patients without white matter lesions (mean decrease 9.3 mm Hg vs 2.0 mm Hg, P = 0.021).
Long-standing hypertension may lead to the development of white matter lesions and dementia by promoting hyalinisation of blood vessel walls and localised atherosclerosis, leading to a reduction in the luminal diameter.
11-14 Subsequent hypotension may lead to hypoperfusion and ischaemia, for example in deep white matter supplied by long penetrating end-arteries with few collaterals. 12, 13 This in turn would lead to demyelination, resulting in disconnection of subcortical-cortical association pathways and the development of dementia.
Although studies such as these have shown a clear association between the development of dementia and previous hypertension, there is evidence that low blood pressure is common in patients with established dementia. 15 This is probably secondary to factors such as sensory deprivation, weight loss, a sedentary life style, and decreased sympathetic outflow from the brain to the cardiovascular system and kidneys. 
The cognitive function hypothesis
These longitudinal and epidemiological studies show a relationship between high blood pressure and subsequent dementia. This suggests that elevated blood pressure increases the risk of decline in cognitive function, and that active lowering of blood pressure should prevent impairment of cognitive function.
Evidence in support of this hypothesis comes from the Systolic Hypertension in Europe (Syst-Eur) Dementia Project. 16 In this study, 2418 patients, aged 60 years and above, with systolic hypertension received antihypertensive therapy or placebo for a median period of 2 years. The median score on the Mini Mental State Examination (MMSE) at baseline was 29; a score below 24 on this scale indicates possible dementia. Compared with placebo, antihypertensive therapy reduced the incidence of dementia from 7.1/1000 patient-years to 3.8 cases/1000 patient years (21 cases vs 11 cases, respectively; risk reduction 50%, P = 0.05). The authors concluded that treating 1000 patients with antihypertensive therapy for 5 years could prevent 19 cases of dementia. 16 A number of smaller studies also support the hypothesis that blood pressure reduction will have a favourable effect on cognitive function. In one study, 69 patients, aged 30-73 years, were treated with the angiotensin II type 1 (AT 1 )-receptor blocker losartan, 50 mg, or hydrochlorothiazide, 25 mg, for 26 months. 17 Cognitive function was measured by means of the MMSE at baseline and at the end of the treatment period. In the losartan group, the mean MMSE score improved from 23 ± 3 to 27 ± 3 (P Ͻ 0.001), whereas no significant change occurred in the hydrochlorothiazide group. The effect of losartan was particularly marked in patients over 60 years of age.
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The SCOPE Study
The impact of antihypertensive treatment on cognitive function in elderly patients is currently being further investigated in the Study on Cognition and Prognosis in the Elderly (SCOPE). 18 The primary aim of this study is to investigate the effect of candesartan cilexetil on major cardiovascular events (non-fatal myocardial infarction, non-fatal stroke, cardiovascular mortality) in elderly patients. A secondary objective is to determine whether treatment of mild hypertension with candesartan prevents a decline in cognitive function, and reduces the incidence of dementia, in elderly nondemented patients.
The SCOPE Study involves a total of 4964 patients from 15 countries. Patients were eligible for inclusion if they were aged between 70 and 89 years, and had a sitting systolic blood pressure of 160-179 mm Hg, a diastolic blood pressure of 90-99 mm Hg, or both; if they were already receiving antihypertensive therapy, this treatment was to be standardised to hydrochlorothiazide, 12.5 mg once daily. In addition, patients were required to have a MMSE score of 24 or above. Following a 1-3-month run-in period, patients were randomised to receive candesartan cilexetil, 8 mg once daily, or matching placebos. The dose was subsequently doubled if necessary to achieve blood pressure control. Treatment will be continued for 3-5 years.
The baseline characteristics of the patients included in the SCOPE Study have been reported previously. 19 The mean age of the patients was 76 years, and most were in the younger (70-79 years) age group; however, approximately 20% were over 80 years of age (Figure 2 ). The ratio of males to females was 36%:64%. The mean blood pressure at randomisation was 166/90 mm Hg, and 52% were receiving antihypertensive therapy. Approximately 22% were receiving treatment with non-steroidal anti-inflammatory drugs or aspirin; 9% were receiving lipid-lowering drugs and 8% were being treated with psychopharmacological agents. There was a relatively low incidence of previous cardiovascular disease: myocardial infarction, stroke and atrial fibrillation had each occurred in 4% of patients. The mean MMSE score at baseline was 28, and only a small proportion of patients had scores indicating possible borderline dementia (Figure 3) .
The results of the SCOPE Study are of great poten- tial significance since there is as yet no outcome trial with AT 1 -blockers in hypertension alone, and no large-scale trial that is evaluating the effect of treatment on cognitive function in elderly hypertensive patients. The study was scheduled to close in February 2002.
Rationale for use of candesartan in SCOPE
Candesartan represents a rational choice for the treatment of mild hypertension in elderly patients, for a number of reasons. Controlled clinical trials have shown that once-daily treatment with candesartan provides effective blood pressure control irrespective of age, gender, or baseline diastolic blood pressure. [20] [21] [22] [23] Furthermore, clinical trials and metaanalyses have shown that candesartan is as well tolerated in elderly patients (Ͼ65 years) as in younger patients, with an adverse event profile comparable with that of placebo. 20, 24 The good efficacy and tolerability of candesartan in elderly patients has been illustrated by a recent study, 22 in which 184 patients over 75 years of age were randomised to receive candesartan cilexetil, 8-16 mg, or hydrochlorothiazide, 12.5-25 mg, for 24 weeks. The two treatments produced similar reductions in systolic and diastolic blood pressures, and were generally well tolerated. However, hypokalaemia and hyperuricaemia were reported by 7-8% of patients in the hydrochlorothiazide group, but were not seen during treatment with candesartan.
An important issue in elderly patients is the risk of orthostatic hypotension during antihypertensive therapy. This was investigated in a study involving 193 patients, aged 65 years and above, who were randomised to receive candesartan cilexetil, 8-16 mg, or placebo for 12 weeks. 21 Treatment with candesartan had no effect on the normal orthostatic response to standing (Figure 4 ).
Conclusions
In addition to being a risk factor for cardiovascular disease, hypertension in elderly patients is associated with an increased risk of cognitive impairment and dementia. There is some evidence that antihypertensive therapy may prevent or reduce cognitive impairment and dementia, but a large outcome study is needed to confirm these findings.
The SCOPE Study will provide important data on the impact of antihypertensive therapy with candesartan in elderly patients with 'mild' hypertension, both in terms of cardiovascular events, cognitive function and dementia. The study will thus provide valuable insights into the long-term benefits of antihypertensive treatment with AT 1 -receptor blockers, and contribute to answering the question of whether these agents offer benefits that extend beyond blood pressure reduction, particularly with regard to cognitive function and the development of dementia. 21 Blood pressure was measured with the patient supine, and immediately and 2 minutes after standing. Data are presented as means and 95% confidence intervals.
